FDA approval based on robust Phase III data in which Cosentyx ® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 2 1 As the only IL-17A inhibitor ...

Novartis NVS announced that a late-stage study of its interleukin-17A inhibitor, Cosentyx (secukinumab), has failed to meet the primary endpoint of sustained remission at week 52 for a new indication ...

EAST HANOVER, N.J., July 3, 2025 /PRNewswire/ -- Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx ® (secukinumab) in adults with newly diagnosed or ...

Novartis AGNVS reported first-quarter 2017 core earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.10 but it was lower than the year-ago figure of $1.17. Revenues declined 1% to ...

Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx™ (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes ...

Diplomat Pharmacy, Inc. (NYSE: DPLO) has been selected to the Novartis limited-distribution panel to distribute COSENTYX™ (secukinumab), a drug approved in January by the U.S. Food and Drug ...

Polymyalgia rheumatica is the second most common inflammatory rheumatic disease in adults aged 50 years and older, typically characterized by acute pain and stiffness in the shoulders, neck, and hips.

The Pharmaceutical Research and Manufacturers of America (PhRMA) outlined initiatives to bolster U.S. manufacturing, ease patient costs, and improve access to medicine. The trade group emphasized that ...

At least one European pharmaceutical giant seems to have gotten President Donald Trump’s message about bringing manufacturing to the U.S.: The maker of top-selling drugs like heart medicine Entresto ...

A late-stage trial testing Novartis’ Cosentyx in individuals with giant cell arteritis failed to meet its primary endpoint. The phase 3 study tested Cosentyx alongside a 26-week steroid taper and ...